Type 2 diabetes mellitus is a disease with increasing prevalence worldwide. It is associated with long-term damage to
several organs. Treatment should be initiated as soon as possible after detection of diabetes. The basis of treatment is
with metformin. The most recent oral antidiabetic agents include DPP-4 inhibitors and SGLT-2 inhibitors. Based on the
results of the completed studies, we can positively stratify their efficacy, low risk of hypoglycemia, renal and cardiovascular
neutrality, protection (depending on the molecule). The treatment with these preparations should reflect the
individual needs of the patient, taking into account their renal and hepatic safety and the possibility of causing adverse
effects resulting from the mechanism of their immune system.